Related Experiment Videos
Aphthous stomatitis and its management.
1Department of Oral Pathology and Medicine, Tufts University School of Dental Medicine, Boston.
Current Opinion in Dentistry
|December 1, 1991
Summary
Recurrent aphthous stomatitis is challenging to treat due to unknown causes. Recent research highlights thalidomide as a potential therapy for this condition.
Area of Science:
- Oral Medicine
- Dermatology
Background:
- Recurrent aphthous stomatitis (RAS) presents significant clinical challenges.
- The exact etiology and pathogenesis of RAS remain incompletely understood.
Purpose of the Study:
- To briefly review the clinical features and etiology of RAS.
- To discuss various therapeutic modalities for RAS.
- To highlight recent literature on thalidomide treatment for RAS.
Main Methods:
- Literature review of clinical features, etiology, and treatment of RAS.
- Discussion of established and emerging therapeutic options.
- Focus on recent studies concerning thalidomide.
Main Results:
- RAS etiology and pathogenesis are not well-established, complicating treatment.
- Multiple treatment options exist, including corticosteroids, antibiotics, and mouth rinses.
- Thalidomide has emerged as a recent focus in RAS treatment literature.
Conclusions:
- Effective treatment for recurrent aphthous stomatitis remains difficult due to unclear causes.
- A range of therapies are available, with thalidomide showing recent promise in research.